Doxapram (hydrochloride hydrate)
Modify Date: 2024-01-02 10:08:30
Doxapram (hydrochloride hydrate) structure
|
Common Name | Doxapram (hydrochloride hydrate) | ||
|---|---|---|---|---|
| CAS Number | 7081-53-0 | Molecular Weight | 432.983 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H33ClN2O3 | Melting Point | 217-219° | |
| MSDS | N/A | Flash Point | N/A | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of Doxapram (hydrochloride hydrate)Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.Target: Potassium ChannelDoxapram is a respiratory stimulant. Doxapram (15-150 microM) also evoked 3H overflow in a concentration dependent manner, and doxapram-evoked release was inhibited by the Ca2+ channel blocker nifedipine (5 microM). Analysis of released tritiated compounds suggested that doxapram preferentially stimulated the release of dopamine. Our results indicate that the mechanism of action of doxapram shares similarities with that of hypoxia in the carotid body [1]. Doxapram (1-100 microM) caused rapid, reversible and dose-dependent inhibitions of K+ currents recorded in type I cells (IC50 approximately 13 microM). doxapram was also seen to directly inhibit Ca(2+)-independent K+ currents. Doxapram was a more potent inhibitor of the Ca(2+)-activated K+ currents recorded under control conditions. Doxapram (10 microM) was without effect on L-type Ca2+ channel currents recorded under conditions where K+ channel activity was minimized and was also without significant effect on K+ currents recorded in the neuronal cell line NG-108 15, suggesting a selective effect on carotid body type I cells. The effects of doxapram on type I cells show similarities to those of the physiological stimuli of the carotid body, suggesting that doxapram may share a similar mechanism of action in stimulating the intact organ [2]. |
| Name | doxapram hydrochloride monohydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.Target: Potassium ChannelDoxapram is a respiratory stimulant. Doxapram (15-150 microM) also evoked 3H overflow in a concentration dependent manner, and doxapram-evoked release was inhibited by the Ca2+ channel blocker nifedipine (5 microM). Analysis of released tritiated compounds suggested that doxapram preferentially stimulated the release of dopamine. Our results indicate that the mechanism of action of doxapram shares similarities with that of hypoxia in the carotid body [1]. Doxapram (1-100 microM) caused rapid, reversible and dose-dependent inhibitions of K+ currents recorded in type I cells (IC50 approximately 13 microM). doxapram was also seen to directly inhibit Ca(2+)-independent K+ currents. Doxapram was a more potent inhibitor of the Ca(2+)-activated K+ currents recorded under control conditions. Doxapram (10 microM) was without effect on L-type Ca2+ channel currents recorded under conditions where K+ channel activity was minimized and was also without significant effect on K+ currents recorded in the neuronal cell line NG-108 15, suggesting a selective effect on carotid body type I cells. The effects of doxapram on type I cells show similarities to those of the physiological stimuli of the carotid body, suggesting that doxapram may share a similar mechanism of action in stimulating the intact organ [2]. |
|---|---|
| Related Catalog | |
| References |
| Melting Point | 217-219° |
|---|---|
| Molecular Formula | C24H33ClN2O3 |
| Molecular Weight | 432.983 |
| Exact Mass | 432.217957 |
| PSA | 42.01000 |
| LogP | 3.78680 |
| Water Solubility | Soluble in water, in alcohol and in methylene chloride. |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | Missing Phrase - N15.00950417 |
| RIDADR | UN 2811 6.1 / PGIII |
|
Doxapram and hypokalaemia in very preterm infants.
Arch. Dis. Child Fetal Neonatal Ed. 98(5) , F416-8, (2013) We observed two preterm infants who developed severe hypokalaemia following doxapram. We therefore wished to review the possible association between doxapram and severe hypokalaemia.A retrospective st... |
|
|
Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs.
J. Pharmacol. Toxicol. Methods 62(1) , 47-53, (2010) Assessing the effects of new chemical entities on respiratory function in animal models is an essential component of preclinical drug safety evaluation. Methods currently available for measuring venti... |
|
|
Acid-sensitive channel inhibition prevents fetal alcohol spectrum disorders cerebellar Purkinje cell loss.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(2) , R596-603, (2008) Ethanol is now considered the most common human teratogen. Educational campaigns have not reduced the incidence of ethanol-mediated teratogenesis, leading to a growing interest in the development of t... |
| 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate |
| UNII:P5RU6UOQ5Y |
| Doxapram hydrochloride monohydrate |
| Dopram |
| Doxapram HCL |
| Stimulexin |
| Doxapram monohydrochloride monohydrate |
| AHR 619 |
| Doxapram Hydrochloride hydrate |
| 1-Ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-2-pyrrolidinone hydrochloride hydrate |
| Dopram (TN) |
| 2-Pyrrolidinone, 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-, hydrochloride, hydrate (1:1:1) |
| 1-Ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one hydrochloride hydrate |
| Doxapram Hydrochloride |
| 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one,hydrate,hydrochloride |
| 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone hydrochloride hydrate |
| Doxapram HCl H2O |
| Doxapram (hydrochloride hydrate) |